Telephonetics VIP receive the ISO 9001 stamp of approval for world class quality control and efficiency

6th June, 2008 - Telephonetics VIP (www.telephoneticsVIP.co.uk), the speech recognition and voice automation specialist, has passed its annual ISO 9001 assessment. Telephonetics VIP has enjoyed accreditation since 1996 in recognition of quality control and efficiency. The ISO 9001 is one of the world’s most established quality frameworks, in use by over three quarters of a million organisations in 161 countries. Read more: Telephonetics VIP receive the ISO 9001 stamp of approval for world class quality

June 6th

Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer

Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today a research collaboration with The University of Texas M. D. Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA- based diagnostic test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.

Current treatment for lung cancer includes surgical resection which may be followed by adjuvant therapy. While patients with high risk of recurrence may benefit from adjuvant therapy, those with low risk of recurrence may be exposed to unnecessary toxicities. The goal of this collaboration is to develop a test that will enable physicians to distinguish between patients with high and low risk of recurrence to optimize treatment regimens. Read more: Rosetta Genomics Ltd ( ROSG )

June 6th

Sopra Group Announces a Plan of Merger, via its Subsidiary Axway, with Tumbleweed Communications

Sopra Group (Euronext Paris: SOP) and Tumbleweed Communications (Nasdaq: TMWD) today announced a plan of merger in which Sopra Group, via its subsidiary Axway, would acquire all the outstanding Tumbleweed stock in cash at $2.70 per share. The proposed transaction is subject to customary closing conditions including regulatory and Tumbleweed stockholder approvals, and is expected to close in the third calendar quarter of 2008. Tumbleweed’s operations will then be combined with those of Axway. Together, Axway and Tumbleweed will offer integrated collaborative business solutions to more than 11,000 customers globally. Read more: Tumbleweed Communications ( TMWD )

June 6th

Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis

Detailed Results to Be Presented at North American Cystic Fibrosis Conference in October 2008

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today top-line results from the 352-patient, double-blind, 24-week placebo-controlled portion of its Phase 3 trial (TIGER-1) with denufosol tetrasodium inhalation solution for the treatment of cystic fibrosis (CF).

The trial demonstrated statistical significance for its primary efficacy endpoint, which was the change in FEV1 (Forced Expiratory Volume in One Second) from baseline at the trial endpoint (at 24 weeks or last observation carried forward). Patients treated with denufosol had a statistically significant improvement in FEV1 compared to placebo (45 milliliter treatment group difference, p = 0.047). On average, patients on denufosol improved relative to baseline whereas patients on placebo remained essentially unchanged. Read more: Inspire Pharmaceuticals Inc ( ISPH )